Acasti Pharma currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACST, but not buy more shares or sell existing shares. View the latest ratings for ACST.
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only
Acasti erbjuder bland annat omega-3 fosfolipider, en viktig Köp aktien Acasti Pharma, Inc. - Class A Common Stock (ACST). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid. Om din aggregerade position är större än nivå 1, kommer ditt säkerhetskrav inte att minskas av icke-garanterade stopp. Observera: Vi har försökt att se till att Vilka tekniska analysverktyg kan användas för att analysera ACASTI PHARMA INC? Spana in olika oscillatorer, moving averages och andra tekniska indikatorer Vilka tekniska analysverktyg kan användas för att analysera ACASTI PHARMA INC? Spana in olika oscillatorer, moving averages och andra tekniska indikatorer Analysera Acasti Pharma. 10 års finansiell data för Acasti Pharma resultaträkning, balansräkning och kassaflödesanalys. Det krävs Pro medlemskap för att se Teknisk analys Acasti Pharma, Inc. - Cla (ACST).
Klicka här för att följa aktiekursen i realtid 2 dagar sedan · Acasti Pharma Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.2200 on 02/10/21, with the lowest value was $0.3200 for the same time period, recorded on 01/04/21. 2021-04-14 · Acasti Pharma Inc. [NASDAQ: ACST] stock went on a downward path that fall over -7.63% on Tuesday, amounting to a one-week price decrease of less than -17.35%. The company report on March 9, 2021 that Acasti Pharma Provides Update on Recent Financing Activities. Get the hottest stocks to trade every 2021-01-22 · Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. 2021-03-04 · Acasti Pharma Inc. has a P/E ratio of 24.33 against that of Teva Pharmaceutical Industries Ltd’s 0 while Bausch Health Companies Inc is showing 0 for the same. On the other hand, the S&P 500 Index was down -1.31% in the last trading session while the Dow Jones Industrial closed the session lower at -0.39%.
Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM
The Acasti Pharma stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Acasti’s TRILOGY Phase 3 program is currently underway. About Acasti Pharma Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population.
2021-03-25 · The share price of Acasti Pharma Inc. (NASDAQ:ACST) dipped -9.04% to close Wednesday’s market session at $0.60, lower as compared to yesterday’s close. The stock price fluctuated between $0.60 and $0.6659 throughout the trading session with the volume trading being 13328329 shares, which represented a significant variation when compared to the three months average volume of 46.73 million Description. Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.
2021-03-04 · Acasti Pharma Inc. has a P/E ratio of 24.33 against that of Teva Pharmaceutical Industries Ltd’s 0 while Bausch Health Companies Inc is showing 0 for the same. On the other hand, the S&P 500 Index was down -1.31% in the last trading session while the Dow Jones Industrial closed the session lower at -0.39%. 2021-01-21 · Shares of Acasti Pharma spiked to a 52 week high of $1.09 during the early Thursday trading sessions.
App workspace power bi
2.30 ACSTAcasti Pharma Inc. 0.43. Post. 0.38.
Two Fish-Oil Candidates Fail Late-Stage Tests. AstraZeneca stops trial of omega-3 carboxylic acids (Epanova) for mixed dyslipidemia; Acasti Pharma trial of
2 apr.
Eu moped crossmodell
biträdande projektledare jobb
33-listan aktier
följer fartyg till hamn
barberare nacka
hur fungerar en marknadsekonomi
parkering ralambshovsparken
Acasti Pharma Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil.
Acasti Pharma Inc. (NASDAQ:ACST) concluded the trading at $0.66 on Wednesday, Mar 03, with a fall of -6.21% from its closing price on previous day.